Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials

Journal of Clinical Oncology

Volumn 33, Issue 1, 2015, Pages 36-41

  Sharma, Manish R ^a   Gray, Elizabeth ^a   Goldberg, Richard M ^b   Sargent, Daniel J ^c   Karrison, Theodore G ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; COMPUTER SIMULATION; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SAMPLING; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DISEASE COURSE; DRUG EFFECTS; KAPLAN MEIER METHOD; METASTASIS; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84920612560     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.2826     Document Type: Article

References (32)

1. DiMasi JA, Reichert JM, Feldman L, et al.: Clinical approval success rates for investigational cancer drugs. Clin Pharmacol Ther 94:329-335, 2013
2. Tang H, Foster NR, Grothey A, et al.: Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol 28:1936-1941, 2010
3. Sharma MR, Stadler WM, Ratain MJ: Randomized phase II trials: A long-term investment with promising returns. J Natl Cancer Inst 103:1093-1100, 2011
4. Seymour L, Ivy SP, Sargent D, et al.: The design of phase II clinical trials testing cancer therapeutics: Consensus recommendations from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 16:1764-1769, 2010
5. Eisenhauer EA, Therasse P, Bogaerts J., et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
6. Buyse M, Burzykowski T, Carroll K., et al.: Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218-5224, 2007
7. Tang PA, Bentzen SM, Chen E.X., et al.: Surrogate end points for median overall survival in meta-static colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:4562-4568, 2007
8. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al.: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987-1992, 2008
9. Halabi S, Rini B, Escudier B., et al.: Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer 120:52-60, 2014
10. Laporte S, Squifflet P, Baroux N., et al.: Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: Evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open [epub ahead of print on March 13, 2013]
11. Lavin PT: An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 4:451-457, 1981
12. Karrison TG, Maitland ML, Stadler W.M., et al.: Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99:1455-1461, 2007
13. Jaki T, André V, Su TL, et al.: Designing exploratory cancer trials using change in tumour size as primary endpoint. Stat Med 32:2544-2554, 2013
14. Jain RK, Lee JJ, Ng C, et al.: Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 30:2684-2690, 2012
15. Claret L, Girard P, Hoff P.M., et al.: Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 27:4103-4108, 2009
16. Wang Y, Sung C, Dartois C., et al.: Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 86:167-174, 2009
17. Claret L, Gupta M, Han K., et al.: Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol 31:2110-2114, 2013
18. Sharma MR, Karrison TG, Jin Y, et al.: Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res 18:2309-2315, 2012
19. Goldberg RM, Sargent DJ, Morton R.F., et al.: A randomized controlled trial of fluorouracil plus leuco-vorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colo-rectal cancer. J Clin Oncol 22:23-30, 2004
20. Sanoff HK, Sargent DJ, Campbell M.E., et al.: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26:5721-5727, 2008
21. US Department of Health and Human Services: Guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics. http://www.fda.gov/downloads/drugsGuidanceComplianceRegulatoyInformation/Guidance/UCM071590.pdf
22. Goldberg RM, Sargent DJ, Morton R.F., et al.: NCCTG study N9741: Leveraging learning from an NCI Cooperative Group phase III trial. Oncologist 14:970-978, 2009
23. Sharma MR, Schilsky RL: Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol 9:208-214, 2012
24. Wason JM, Seaman SR: Using continuous data on tumour measurements to improve inference in phase II cancer studies. Stat Med 32:4639-4650, 2013
25. Oxnard GR, Zhao B, Sima C.S., et al.: Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol 29:3114-3119, 2011
26. Zhao B, Oxnard GR, Moskowitz C.S., et al.: A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 16:4647-4653, 2010
27. Zhao B, Tan Y, Bell D.J., et al.: Exploring intra-and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. Eur J Radiol 82:959-968, 2013
28. Kaiser LD: Tumor burden modeling versus progression-free survival for phase II decision making. Clin Cancer Res 19:314-319, 2013
29. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649, 2009
30. An MW, Mandrekar SJ, Branda M.E., et al.: Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clin Cancer Res 17:6592-6599, 2011
31. Huen JM, Grothey A, Branda M.E., et al.: Tumor status at 12 weeks predicts survival in advanced colorectal cancer: Findings from NCCTG N9741. Oncologist 16:859-867, 2011
32. Sargent DJ, Buyse M, Matheson A., et al.: The ARCAD clinical trials program: An update and invitation. Oncologist 17:188-191, 2012